<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719537</url>
  </required_header>
  <id_info>
    <org_study_id>2008-054</org_study_id>
    <nct_id>NCT00719537</nct_id>
  </id_info>
  <brief_title>Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia</brief_title>
  <official_title>Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia in Patients With a Prior History of Preeclampsia: A Prospective, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Uckele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether low dose aspirin combined with progesterone will decrease the
      risk of preeclampsia in pregnant women with a history of preeclampsia in a previous
      pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent advances have shown that certain proteins may be present in a pregnant woman's blood
      very early in pregnancy which can predict who is at the highest risk for developing
      preeclampsia. These proteins can be measured and may be used to predict a woman's risk of
      developing preeclampsia.

      Special placental cells called endovascular cytotrophoblasts are needed in the early
      formation of the placenta. These placental cells invade the maternal blood vessels in the
      formation of the maternal-placental blood interface. Human Leukocytes Antigen-G (HLA-G) is a
      protein produced by the placental cells and prevents these special cells from being rejected
      by the mother's immune system. Recent studies have indicated that the level of HLA-G is
      decreased in placentas from mothers with preeclampsia. Progesterone, a naturally occurring
      hormone produced in pregnancy, has been shown to increase the production of HLA-G in the
      placental cytotrophoblast cells.

      In regards to the treatment of preeclampsia, studies have shown that low dose aspirin if
      given to mothers who have had severe early preeclampsia, lowers the risk for having
      preeclampsia again. This study aims to show that low dose aspirin combined with progesterone
      will decrease the risk of preeclampsia in pregnant women with a history of preeclampsia in a
      previous pregnancy. Data generated will determine levels and ratios of blood proteins that
      are predictive of preeclampsia at specific gestational ages.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    inability to find qualifying participants
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Preeclampsia</measure>
    <time_frame>second and third trimester of pregnancy</time_frame>
    <description>Number of Participants with preeclampsia in second and third trimester of pregnancy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Aspirin plus Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Aspirin 81 mg, given orally once per day Drug: Placebo tablet given orally, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin plus Progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Aspirin 81mg, given orally once per day Drug: Progesterone 200mg given orally, once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 81 mg once a day</description>
    <arm_group_label>Aspirin plus Placebo Oral Tablet</arm_group_label>
    <arm_group_label>Aspirin plus Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo 1 tab Daily</description>
    <arm_group_label>Aspirin plus Placebo Oral Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Oral Progesterone 200 mg Twice Daily</description>
    <arm_group_label>Aspirin plus Progesterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant patients with a previous history of preeclampsia in the immediate preceding
             pregnancy.

          -  18 to 45 years of age will be included.

        Exclusion Criteria:

          -  Patients with chronic hypertension

          -  children (age &lt; 17 years)

          -  Patients that are currently taking anti-psychotics or Selective Serotonin Re-uptake
             Inhibitors

          -  patients on medications which may be detrimental to the study interpretation will also
             be excluded at the principal investigator's discretion.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E Uckele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <results_first_submitted>November 2, 2016</results_first_submitted>
  <results_first_submitted_qc>March 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2017</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>John Uckele</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>preeclampsia</keyword>
  <keyword>progesterone</keyword>
  <keyword>aspirin</keyword>
  <keyword>prevent</keyword>
  <keyword>soluble fms-like tyrosine kinase (sFlt-1)</keyword>
  <keyword>Placental Growth Factor (PlGF)</keyword>
  <keyword>risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No study data is available, will not be shared.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aspirin and Placebo</title>
          <description>Aspirin and placebo: Aspirin 81mg once daily and placebo once daily</description>
        </group>
        <group group_id="P2">
          <title>Aspirin and Progesterone</title>
          <description>aspirin 81 mg once a day oral progesterone 200mg twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aspirin and Placebo</title>
          <description>Aspirin and placebo: Aspirin 81mg once daily and placebo once daily</description>
        </group>
        <group group_id="B2">
          <title>Aspirin and Progesterone</title>
          <description>aspirin 81 mg once a day oral progesterone 200mg twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>18-50 years, female</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Preeclampsia</title>
        <description>Number of Participants with preeclampsia in second and third trimester of pregnancy.</description>
        <time_frame>second and third trimester of pregnancy</time_frame>
        <population>1 Participant withdrawn in aspirin and placebo group, one participant lost to followup in aspirin and progesterone group.</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin and Placebo</title>
            <description>Aspirin and placebo: Aspirin 81mg once daily and placebo once daily</description>
          </group>
          <group group_id="O2">
            <title>Aspirin and Progesterone</title>
            <description>aspirin 81 mg once a day oral progesterone 200mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Preeclampsia</title>
          <description>Number of Participants with preeclampsia in second and third trimester of pregnancy.</description>
          <population>1 Participant withdrawn in aspirin and placebo group, one participant lost to followup in aspirin and progesterone group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aspirin and Placebo</title>
          <description>Aspirin and placebo: Aspirin 81mg once daily and placebo</description>
        </group>
        <group group_id="E2">
          <title>Aspirin and Progesterone</title>
          <description>Aspirin and progesterone: aspirin 81 mg once a day oral progesterone 200mg twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Uckele</name_or_title>
      <organization>William Beaumont Hospital</organization>
      <phone>2485510610</phone>
      <email>john.uckele@beaumont.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

